...
首页> 外文期刊>Journal of Cancer Research and Therapeutics >Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension
【24h】

Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension

机译:经颈静脉肝内门体分流术治疗门静脉高压症的肝细胞癌危险因素调查及生存分析

获取原文
           

摘要

Objective: This study aimed to explore the risk factors of hepatocellular carcinoma (HCC) and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt (TIPS) in treating portal hypertension. Materials and Methods: A retrospective database review was performed, including 106 patients (33 females and 73 males; aged 26–68 years with mean age of 55.3 ± 9.1 years) who received TIPS for treating recurrent gastroesophageal variceal bleeding or refractory ascites with portal hypertension. All the patients were recruited from the Interventional Oncology Department at Beijing Ditan Hospital between October 2008 and December 2011. The TIPS was successfully performed on all involved patients by puncturing at the right branch of portal vein via right hepatic vein. After TIPS, the patients were consecutively followed up at the outpatient clinic. The patients were examined by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen every 3 months for 3 years, for detecting the occurrence of malignant nodules and early HCC. The post-TIPS medical database was reviewed with univariate and multivariate analysis to identify the risk factors for new nodules retrospectively. Results: The overall incidence of HCC was 38.7% (41/106). The multivariate analysis showed that an increased odds ratios (OR) of HCC was observed in the complication of portal hypertension (OR, 0.396; 95% confidence interval [CI], 0.171–0.918; P = 0.031) and preoperative cirrhosis classification (OR, 0.060; 95% CI, 0.021–0.175; P = 0.000). P P = 0.18). The cumulative incidence of new nodules was significantly lower among patients with refractory ascites than those with upper gastrointestinal hemorrhage. Specifically, the survival rates of patients with upper gastrointestinal hemorrhage at years 1, 2, and 3 were 100%, 65%, and 51%, respectively, compared to 100%, 88%, and 85% corresponding to patients with refractory ascites (P = 0.009). The cumulative incidence of HCC was significantly lower in cirrhosis patients with CT identified grade III than those with grade IV. At years 1, 2, and 3, the survival rates of cirrhosis patients with CT identified grade IV were 96%, 22%, and 20%, respectively, compared to 100%, 98%, and 90% in controls (P = 0.012). Conclusions: The identification of clinical variables associated with increased risks of HCC may be useful for selecting appropriate candidates for TIPS. Results suggested that the patients with cirrhosis of CT identified grade IV and with upper gastrointestinal hemorrhage might be relevant to increased odds of HCC after TIPS.
机译:目的:本研究旨在探讨经颈静脉肝内门体分流术(TIPS)治疗门静脉高压症后肝细胞癌(HCC)的危险因素和生存分析。资料和方法:回顾性数据库审查,包括106例接受TIPS治疗复发性胃食管静脉曲张破裂出血或难治性腹水伴门静脉高压症的患者(33例女性和73例男性;年龄26-68岁,平均年龄55.3±9.1岁)。 。所有患者均于2008年10月至2011年12月间从北京地坛医院介入肿瘤科招募。TIPS通过右肝静脉在门静脉右分支穿刺成功地对所有相关患者进行了TIPS。 TIPS后,对患者进行门诊连续随访。每隔3个月,每3个月对腹部进行对比增强X线断层扫描(CT)或磁共振成像(MRI)检查,以检测恶性结节和早期HCC的发生。对TIPS后的医学数据库进行单因素和多因素分析,以回顾性确定新结节的危险因素。结果:HCC的总发生率为38.7%(41/106)。多元分析表明,在门静脉高压并发症(OR,0.396; 95%置信区间[CI],0.171–0.918; P = 0.031)和术前肝硬化分类(OR,0.30)中,HCC的优势比(OR)增加。 0.060; 95%CI,0.021-0.175; P = 0.000)。 P P = 0.18)。顽固性腹水患者新结节的累积发生率明显低于上消化道出血患者。具体而言,上消化道出血患者在第1、2和3年的生存率分别为100%,65%和51%,而顽固性腹水患者的生存率分别为100%,88%和85%( P = 0.009)。 CT鉴定为III级的肝硬化患者的HCC累积发生率明显低于IV级。在第1、2和3年,经CT鉴定为IV级的肝硬化患者的存活率分别为96%,22%和20%,而对照组为100%,98%和90%(P = 0.012) )。结论:确定与HCC风险增加相关的临床变量可能有助于选择合适的TIPS候选人。结果表明,CT肝硬化患者被鉴定为IV级并伴有上消化道出血,可能与TIPS后HCC发生几率增加有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号